Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Infection and Immunity logoLink to Infection and Immunity
. 1997 Dec;65(12):4996–5002. doi: 10.1128/iai.65.12.4996-5002.1997

Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection.

P Ghiara 1, M Rossi 1, M Marchetti 1, A Di Tommaso 1, C Vindigni 1, F Ciampolini 1, A Covacci 1, J L Telford 1, M T De Magistris 1, M Pizza 1, R Rappuoli 1, G Del Giudice 1
PMCID: PMC175721  PMID: 9393788

Abstract

Chronic infection of the gastroduodenal mucosae by the gram-negative spiral bacterium Helicobacter pylori is responsible for chronic active gastritis, peptic ulcers, and gastric cancers such as adenocarcinoma and low-grade gastric B-cell lymphoma. The success of eradication by antibiotic therapy is being rapidly hampered by the increasing occurrence of antibiotic-resistant strains. An attractive alternative approach to combat this infection is represented by the therapeutic use of vaccines. In the present work, we have exploited the mouse model of persistent infection by mouse-adapted H. pylori strains that we have developed to assess the feasibility of the therapeutic use of vaccines against infection. We report that an otherwise chronic H. pylori infection in mice can be successfully eradicated by intragastric vaccination with H. pylori antigens such as recombinant VacA and CagA, which were administered together with a genetically detoxified mutant of the heat-labile enterotoxin of Escherichia coli (referred to as LTK63), in which the serine in position 63 was replaced by a lysine. Moreover, we show that therapeutic vaccination confers efficacious protection against reinfection. These results represent strong evidence of the feasibility of therapeutic use of VacA- or CagA-based vaccine formulations against H. pylori infection in an animal model and give substantial preclinical support to the application of this kind of approach in human clinical trials.

Full Text

The Full Text of this article is available as a PDF (955.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atherton J. C., Cao P., Peek R. M., Jr, Tummuru M. K., Blaser M. J., Cover T. L. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem. 1995 Jul 28;270(30):17771–17777. doi: 10.1074/jbc.270.30.17771. [DOI] [PubMed] [Google Scholar]
  2. Blaser M. J., Parsonnet J. Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest. 1994 Jul;94(1):4–8. doi: 10.1172/JCI117336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blaser M. J., Perez-Perez G. I., Kleanthous H., Cover T. L., Peek R. M., Chyou P. H., Stemmermann G. N., Nomura A. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995 May 15;55(10):2111–2115. [PubMed] [Google Scholar]
  4. Censini S., Lange C., Xiang Z., Crabtree J. E., Ghiara P., Borodovsky M., Rappuoli R., Covacci A. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14648–14653. doi: 10.1073/pnas.93.25.14648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chen M., Lee A., Hazell S. Immunisation against gastric helicobacter infection in a mouse/Helicobacter felis model. Lancet. 1992 May 2;339(8801):1120–1121. doi: 10.1016/0140-6736(92)90720-n. [DOI] [PubMed] [Google Scholar]
  6. Corthésy-Theulaz I., Porta N., Glauser M., Saraga E., Vaney A. C., Haas R., Kraehenbuhl J. P., Blum A. L., Michetti P. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology. 1995 Jul;109(1):115–121. doi: 10.1016/0016-5085(95)90275-9. [DOI] [PubMed] [Google Scholar]
  7. Covacci A., Censini S., Bugnoli M., Petracca R., Burroni D., Macchia G., Massone A., Papini E., Xiang Z., Figura N. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5791–5795. doi: 10.1073/pnas.90.12.5791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Covacci A., Falkow S., Berg D. E., Rappuoli R. Did the inheritance of a pathogenicity island modify the virulence of Helicobacter pylori? Trends Microbiol. 1997 May;5(5):205–208. doi: 10.1016/S0966-842X(97)01035-4. [DOI] [PubMed] [Google Scholar]
  9. Cover T. L., Tummuru M. K., Cao P., Thompson S. A., Blaser M. J. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains. J Biol Chem. 1994 Apr 8;269(14):10566–10573. [PubMed] [Google Scholar]
  10. Cuenca R., Blanchard T. G., Czinn S. J., Nedrud J. G., Monath T. P., Lee C. K., Redline R. W. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology. 1996 Jun;110(6):1770–1775. doi: 10.1053/gast.1996.v110.pm8964402. [DOI] [PubMed] [Google Scholar]
  11. D'Elios M. M., Manghetti M., De Carli M., Costa F., Baldari C. T., Burroni D., Telford J. L., Romagnani S., Del Prete G. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol. 1997 Jan 15;158(2):962–967. [PubMed] [Google Scholar]
  12. Di Tommaso A., Saletti G., Pizza M., Rappuoli R., Dougan G., Abrignani S., Douce G., De Magistris M. T. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun. 1996 Mar;64(3):974–979. doi: 10.1128/iai.64.3.974-979.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Doidge C., Crust I., Lee A., Buck F., Hazell S., Manne U. Therapeutic immunisation against Helicobacter infection. Lancet. 1994 Apr 9;343(8902):914–915. doi: 10.1016/s0140-6736(94)90032-9. [DOI] [PubMed] [Google Scholar]
  14. Douce G., Fontana M., Pizza M., Rappuoli R., Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun. 1997 Jul;65(7):2821–2828. doi: 10.1128/iai.65.7.2821-2828.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Eck M., Schmausser B., Haas R., Greiner A., Czub S., Müller-Hermelink H. K. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology. 1997 May;112(5):1482–1486. doi: 10.1016/s0016-5085(97)70028-3. [DOI] [PubMed] [Google Scholar]
  16. Ferrero R. L., Thiberge J. M., Huerre M., Labigne A. Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection. Infect Immun. 1994 Nov;62(11):4981–4989. doi: 10.1128/iai.62.11.4981-4989.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ferrero R. L., Thiberge J. M., Kansau I., Wuscher N., Huerre M., Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6499–6503. doi: 10.1073/pnas.92.14.6499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Figura N. Mouth-to-mouth resuscitation and Helicobacter pylori infection. Lancet. 1996 May 11;347(9011):1342–1342. doi: 10.1016/s0140-6736(96)90996-4. [DOI] [PubMed] [Google Scholar]
  19. Ghiara P., Marchetti M., Blaser M. J., Tummuru M. K., Cover T. L., Segal E. D., Tompkins L. S., Rappuoli R. Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infect Immun. 1995 Oct;63(10):4154–4160. doi: 10.1128/iai.63.10.4154-4160.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Goddard A. F., Logan R. P. Antimicrobial resistance and Helicobacter pylori. J Antimicrob Chemother. 1996 Apr;37(4):639–643. doi: 10.1093/jac/37.4.639. [DOI] [PubMed] [Google Scholar]
  21. Haeberle H. A., Kubin M., Bamford K. B., Garofalo R., Graham D. Y., El-Zaatari F., Karttunen R., Crowe S. E., Reyes V. E., Ernst P. B. Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in the human gastric mucosa. Infect Immun. 1997 Oct;65(10):4229–4235. doi: 10.1128/iai.65.10.4229-4235.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Harris P. R., Cover T. L., Crowe D. R., Orenstein J. M., Graham M. F., Blaser M. J., Smith P. D. Helicobacter pylori cytotoxin induces vacuolation of primary human mucosal epithelial cells. Infect Immun. 1996 Nov;64(11):4867–4871. doi: 10.1128/iai.64.11.4867-4871.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lee A., O'Rourke J., De Ungria M. C., Robertson B., Daskalopoulos G., Dixon M. F. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology. 1997 Apr;112(4):1386–1397. doi: 10.1016/s0016-5085(97)70155-0. [DOI] [PubMed] [Google Scholar]
  24. Lee C. K., Weltzin R., Thomas W. D., Jr, Kleanthous H., Ermak T. H., Soman G., Hill J. E., Ackerman S. K., Monath T. P. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis. 1995 Jul;172(1):161–172. doi: 10.1093/infdis/172.1.161. [DOI] [PubMed] [Google Scholar]
  25. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl. 1993;196:34–37. doi: 10.3109/00365529309098341. [DOI] [PubMed] [Google Scholar]
  26. Manetti R., Massari P., Burroni D., de Bernard M., Marchini A., Olivieri R., Papini E., Montecucco C., Rappuoli R., Telford J. L. Helicobacter pylori cytotoxin: importance of native conformation for induction of neutralizing antibodies. Infect Immun. 1995 Nov;63(11):4476–4480. doi: 10.1128/iai.63.11.4476-4480.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Marchetti M., Aricò B., Burroni D., Figura N., Rappuoli R., Ghiara P. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science. 1995 Mar 17;267(5204):1655–1658. doi: 10.1126/science.7886456. [DOI] [PubMed] [Google Scholar]
  28. Marinaro M., Staats H. F., Hiroi T., Jackson R. J., Coste M., Boyaka P. N., Okahashi N., Yamamoto M., Kiyono H., Bluethmann H. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol. 1995 Nov 15;155(10):4621–4629. [PubMed] [Google Scholar]
  29. Michetti P., Corthésy-Theulaz I., Davin C., Haas R., Vaney A. C., Heitz M., Bille J., Kraehenbuhl J. P., Saraga E., Blum A. L. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology. 1994 Oct;107(4):1002–1011. doi: 10.1016/0016-5085(94)90224-0. [DOI] [PubMed] [Google Scholar]
  30. Mohammadi M., Czinn S., Redline R., Nedrud J. Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice. J Immunol. 1996 Jun 15;156(12):4729–4738. [PubMed] [Google Scholar]
  31. Mohammadi M., Redline R., Nedrud J., Czinn S. Role of the host in pathogenesis of Helicobacter-associated gastritis: H. felis infection of inbred and congenic mouse strains. Infect Immun. 1996 Jan;64(1):238–245. doi: 10.1128/iai.64.1.238-245.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Parsonnet J., Friedman G. D., Vandersteen D. P., Chang Y., Vogelman J. H., Orentreich N., Sibley R. K. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991 Oct 17;325(16):1127–1131. doi: 10.1056/NEJM199110173251603. [DOI] [PubMed] [Google Scholar]
  33. Parsonnet J., Hansen S., Rodriguez L., Gelb A. B., Warnke R. A., Jellum E., Orentreich N., Vogelman J. H., Friedman G. D. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994 May 5;330(18):1267–1271. doi: 10.1056/NEJM199405053301803. [DOI] [PubMed] [Google Scholar]
  34. Pizza M., Fontana M. R., Giuliani M. M., Domenighini M., Magagnoli C., Giannelli V., Nucci D., Hol W., Manetti R., Rappuoli R. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J Exp Med. 1994 Dec 1;180(6):2147–2153. doi: 10.1084/jem.180.6.2147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ricci V., Ciacci C., Zarrilli R., Sommi P., Tummuru M. K., Del Vecchio Blanco C., Bruni C. B., Cover T. L., Blaser M. J., Romano M. Effect of Helicobacter pylori on gastric epithelial cell migration and proliferation in vitro: role of VacA and CagA. Infect Immun. 1996 Jul;64(7):2829–2833. doi: 10.1128/iai.64.7.2829-2833.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sakagami T., Dixon M., O'Rourke J., Howlett R., Alderuccio F., Vella J., Shimoyama T., Lee A. Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut. 1996 Nov;39(5):639–648. doi: 10.1136/gut.39.5.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Schütze K., Hentschel E., Dragosics B., Hirschl A. M. Helicobacter pylori reinfection with identical organisms: transmission by the patients' spouses. Gut. 1995 Jun;36(6):831–833. doi: 10.1136/gut.36.6.831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Takahashi I., Marinaro M., Kiyono H., Jackson R. J., Nakagawa I., Fujihashi K., Hamada S., Clements J. D., Bost K. L., McGhee J. R. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis. 1996 Mar;173(3):627–635. doi: 10.1093/infdis/173.3.627. [DOI] [PubMed] [Google Scholar]
  39. Telford J. L., Covacci A., Ghiara P., Montecucco C., Rappuoli R. Unravelling the pathogenic role of Helicobacter pylori in peptic ulcer: potential new therapies and vaccines. Trends Biotechnol. 1994 Oct;12(10):420–426. doi: 10.1016/0167-7799(94)90031-0. [DOI] [PubMed] [Google Scholar]
  40. Telford J. L., Ghiara P., Dell'Orco M., Comanducci M., Burroni D., Bugnoli M., Tecce M. F., Censini S., Covacci A., Xiang Z. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J Exp Med. 1994 May 1;179(5):1653–1658. doi: 10.1084/jem.179.5.1653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Tummuru M. K., Cover T. L., Blaser M. J. Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production. Infect Immun. 1993 May;61(5):1799–1809. doi: 10.1128/iai.61.5.1799-1809.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Tytgat G. N. Antimicrobial therapy for Helicobacter pylori infection. Helicobacter. 1997 Jul;2 (Suppl 1):S81–S88. doi: 10.1111/j.1523-5378.1997.06b01.x. [DOI] [PubMed] [Google Scholar]
  43. Tytgat G. N. Current indications for Helicobacter pylori eradication therapy. Scand J Gastroenterol Suppl. 1996;215:70–73. [PubMed] [Google Scholar]
  44. Weel J. F., van der Hulst R. W., Gerrits Y., Roorda P., Feller M., Dankert J., Tytgat G. N., van der Ende A. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis. 1996 May;173(5):1171–1175. doi: 10.1093/infdis/173.5.1171. [DOI] [PubMed] [Google Scholar]
  45. Xiang Z., Censini S., Bayeli P. F., Telford J. L., Figura N., Rappuoli R., Covacci A. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun. 1995 Jan;63(1):94–98. doi: 10.1128/iai.63.1.94-98.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Yamamoto S., Kiyono H., Yamamoto M., Imaoka K., Fujihashi K., Van Ginkel F. W., Noda M., Takeda Y., McGhee J. R. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A. 1997 May 13;94(10):5267–5272. doi: 10.1073/pnas.94.10.5267. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES